The neoantigen cancer vaccine market generated revenue of USD 24.4 million in 2022, and it is expected to reach USD 1,322.8 million in 2030, with a growth rate of 67.6% during 2023–2030. The major driver for the market is the increment in research activities and the surge in the cases of cancer worldwide. Additionally, due to the increasing importance of personalized cancer vaccines and the increasing economic burden of this disease, pharmaceutical manufacturers are augmenting their R&D efforts.
Personalized neoantigens are mutated antigens that are unique to most neoantigens and completely different across patients. Thus, such drugs can only be given to the person they were made for. This is because personalized tumor neoantigens are highly specific to individuals. Moreover, tumor vaccines targeting neoantigens can effectively induce T-cells, to produce a strong immune response against tumors. The personalized vaccine category, thus, accounted for the larger share in the market in 2022, based on product type.
Research scientists are working on DNA- and RNA-based vaccines. In a recent study on a DNA-based vaccine, it was found that when contained in a nanocarrier, a multiepitope neoantigen vaccine can be used for personalized cancer immunotherapy and as an effective approach to the enrichment of neoantigens. During the research conducted on animals, the DNA-based vaccine effectively inhibited tumor growth and reduced lung metastasis.
Researchers are also working on mRNA-based vaccines, one of which has shown positive results in a recent trial, which would further encourage the exploration of mRNAs to produce cancer vaccines.
A 2021 research article shows that the need for new therapies for lung cancer may be met by promoting tumor-specific immunity from enhanced responses to neoantigens. Data provides proof that T-cell neoantigen immunoreactivity is important in the clinical activity of immunotherapy. Thus, due to the fact that lung cancer is among the most-common malignancies in people, this category will hold the largest market share.
Liver cancer also holds a significant share in the market, as it is the third-biggest cause of death in cancer patients. Several studies are being conducted on neoantigen vaccines for hepatocellular carcinoma (HCC). The trial results of some of them demonstrate that mutations in HCC tumors generate immunogenic neoantigens, which may be applicable to future combination therapeutic strategies. In several recent neoantigen vaccination studies, no adverse events were observed.
The hospitals and clinics category is expected to hold the largest share in the market for neoantigen cancer vaccines during the forecast period, based on end user. Vaccination is most frequently performed in cancer hospitals because it is possible to assemble multidisciplinary teams here.
The increasing prevalence of cancer and the innovations in the healthcare industry have made North America the largest market for neoantigen cancer vaccines. Moreover, the presence of a larger number of players, extensive pipeline of drugs, and rising awareness of such therapies are playing a significant role in the growth of the market in the region.
Asia-Pacific is expected to progress with the highest CAGR over the forecast period. This is primarily due to the improving cancer management ecosystem, surging prevalence of cancer, and increasing vaccine development and manufacturing outsourcing activities in the region.
The increasing frequency of mergers and acquisitions among pharma and biotech companies is expected to drive the market over the forecast period:
The biggest companies in the neoantigen cancer vaccine market are Moderna Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Agenus Inc., OSE Immunotherapeutics, Advaxis Inc., Medigene AG, Neon Therapeutics (Acquired by BioNTech SE), Genocea Biosciences, Immunovative Therapies Ltd., and Gritstone bio.